Appendix 2. A detailed overview of phenotyping program main phase

The following table provides a detailed overview of the phenotyping program of BeLOVE. This includes the phenotyping in the acute phase, during the CRU visits and the telephone of postal follow-up at any time during the planned 10 years of follow-up. Some additional details are described in the text below the table.

Assessment	S	ource Data	a		Time of assessment						
	Medical records	Examin ation	Questi onnair e	T1 (ap)	T2 (dp)	T3 (tel)	T4 (dp)	T5-6 (tel)	T7 (dp)	T8-11 (tel)	T12 (dp)
Demographics											
· Basic demographics			x								
· Sociodemographics			x								
· Gender aspects			x		_						
Health history			x			_	_	_	_	_	_
Health behavior			x								
Medication			x			_		_		_	
Clinical outcomes (endpoints)	х		x								
Anthropometry		х									
Activities of Daily Living Barthel-Index		x	x								
Clinical symptom scales and scores											
• •											
National Institute of Health Stroke Scale (NIHSS) mRS Score		x x	x								
Canadian Cardiovascular Society (CCS) Classification		x	x	_							
New York Heart Association (NYHA) Classification		x	x								
Metabolic function											
· Air displacement plethysmography (BodPod)		x									
· Advanced Glycylation Endproducts (AGE)		x									
Indirect Calorimetry		x									
Meal load vs. physical challenge (randomized 1:1)		x									
14d continuous glucose monitoring		x									
Mediterranean Diet Score			x	_	_		_		_		
Three Factor Eating Questionnaire (TFQ)			x				_				
Food Frequency Questionnaire (FFQ)			x								
Cardiovascular function											
· ECG (12-ch)		x									
· 24h-Holter ECG		x									
· Pulse Wave Analysis		x									
· 24h- blood pressure		x									
· Ankle brachial index		x									
Imaging											
· 3D-echocardiography		x									
· Carotid IMT and plaque Ultrasound		x									
Ocular fundus photography		x									
· Optical coherence tomography (OCT)		x									
· MRI: cranial MRI		x									
· MRI: cardiac MRI		x									
· MRI: metabolic MRI		x									
· MRI: 1H-MRI		х									
Physical function		v	v								
· Frailty Score		X	X								
Nine-hole peg Test Manual force test		X									
Manual force test		X			ш		ш		ш		

 Balance Test 4m gait speed test 2-minute walk test 2-minute finger tapping test 5-Chair-Rise-Test Speed measurement FDM-3/ZEBRIS Mobile accelerometry Physical Fatigue Severity Questionnaire (FSS) 	x x x x x x	x								
Somatosensation • Quantitative sensory testing (CDT, WDT, VDT)	x									
Neurophysiology (sural neurography, laser evoked potentials)	x									
Utah Early Neuropathy Scale (UENS) painDETECT (pDQ) Michigan Neuropathy Screening) Instrument (MNSI=) Survey of Autonomic Symptoms (SAS) Electroencephalography (EEG)	x x	x x x								
Cognitive function			_	_	_	_	_	_	_	_
Montreal Cognitive Assessment (MOCA) Cambridge Neuropsychological Test Automated Battery	x x									
(CANTAB) · Mehrfachwahl-Wortschatz-						_				
Intelligenztest (MWT) Version A	х									
· Performance Test System (Leistungsprüfsystem, LPS-3=	х									
Quality of life (Qol) Patient-Reported Outcomes Measurement Information System (PROMIS) 29 PROMIS: physical function PROMIS: sleep disturbance PROMIS: anxiety PROMIS: depression PROMIS: scale pain intensity PROMIS: pain behavior Short Form (SF-) 36 EuroQol Group (EQ) 5d3l Patient Health Questionnaire (PHQ)-8		x x x x x x x x		0 0000000		0 00000000		0 00000000		
Stroke Specific Quality of Life Scale (SS-QoL) Kansas City Cardiomyopathy Questionnaire (KCCQ) Seattle Angina Questionnaire Rose Dyspnea Scale (elements) Audit of Diabetes Dependent (ADD) QoL		x x x x	0							_ _ _ _
Biosampling										
 Blood sample LB (immediately analyzed) Blood sample BC (immune phenotyping) Blood sample BB (storage) IPS-programming from blood cells Urine Stool Saliva sample 	x x x x x x									

^{*} Acute phenotyping: 1-7 days post event, 4-8 days for patients enrolled due to acute kidney injury respectively

T1: Baseline, T2: Three months, T3: 1year, T4: 2years, T5,6: 3,4 years, T7: 5 years, T8-11: 6-9 years, T12: 10 years; ap: acute phenotyping*; dp: deep phenotyping; tel: telephone follow up

Acute phenotyping

Patients characterized by an acute event will undergo a limited phenotyping procedure 2 to 7 days after the event. This will include blood sampling in fasting state and numerous self-assessment questionnaires. Disease-independent health related QoL (HRQol) is assessed by PROMIS-29 v2.0 Profile (www.healthmeasures.net)[1,2] and EQ-5d-3L (www.euroqol.org)[3]. Disease-specific QoL questionnaires depend on the index event and include the Kansas City Cardiomyopathy Questionnaire[4] (in subjects with AHF as trigger event), Seattle Angina Questionnaire[5] (in subjects with ACS as trigger event) and Stroke Specific Quality of Life Scale (SSQOL)[6](in subjects with AS as trigger event). All questionnaires will be usually completed electronically on mobile devices. A paper version or support for completing the questionnaires will be also provided if necessary. Moreover, 14-day continuous glucose monitoring will be performed using a subcutaneous glucose measurement system (FreeStyle Libre Pro system; Abbott Diabetes Care, US). Therefore, a sensor is placed subcutaneously at the upper arm as described previously [7]. At the time of the acute event, blood samples will be taken 2 to 7 days after the acute event. Theses samples will be only used for immune phenotyping if sampling was performed within the first 3 days after the onset of the acute event. All blood samples will be centrifuged, and plasma and serum samples will be frozen immediately at -80°C. Biosampling also includes buffy coat, urine sampling, saliva, samples and dry blood.

Patients with type 2 diabetes, however with no acute event, will be continuously invited for screening. After inclusion, these patients will undergo comparable phenotyping as acute patients at the time of the acute event. However, disease-specific QoL will be assessed by ADDQoL in these patients [8].

CRU phenotyping

Ninety days (± 7 days) after the acute event a re-invitation of all subjects is intended to perform a comprehensive anthropometric, cardiovascular, metabolic, cognitive, immunological and neurological characterization. This also includes all type 2 diabetics after successful screening. Thus, all subjects will undergo the identical phenotyping procedure at day 90, with the exception for the nature of the stress test.

In detail, following a 12-hour overnight fast all patients will be investigated at one of the three trial centers of the Charité Medical School at 8.00 a.m. Waist circumference will be measured three times and the means will be calculated. Blood, urine, saliva and stool samples will be taken in fasting state. Afterwards, demographic factors, socioeconomic status, lifestyle risk factors (e.g. smoking, alcohol consumption, stress, physical activity, and nutritional habits), health history (e.g. metabolic, cardiovascular, sleep, migraine), female reproductive history, reproductive function as well as physical complaints and sleep disturbances will be evaluated by specific questionnaires. Disease-independent health related QoL (HRQoI) will evaluated again as described for acute-phenotyping. Food frequency questionnaire (FFQ)[9], Three-Factor-Eating-Questionnaire (TFEQ)[10] are used to assess food intake and eating behavior. Moreover, patients will be asked about the course of their index-event related complaints since study inclusion and their concurrent medication. In case the participant was included due to a cerebrovascular event disease-specific etiological classification (TOAST in ischemic stroke; ABCD2 in TIA) is pursued on the basis of medical records of the index event.

Basal characterisation

Basal characterization includes assessment of body weight and height (Seca 764/Seca 799, Seca, Germany). Waist/hip and head circumference will be measured three times and the means were calculated. Blood pressure and heart rate will be analyzed likewise (Boso Carat Professional Bosch + Sohn. Germany), with the participants lying in the horizontal position for 10 min and means will be calculated derived from 3 consecutive measures [11]. 12-channel-ECG (MAC 1600 EKG, GE Medical Systems Information Technologies GmbH, Germany) will be also performed in all participants.A 12-channel-ECG (MAC 1600 EKG, GE Medical Systems Information Technologies GmbH, Germany) will be also performed at rest in each participant.

Moreover fasting blood samples as well as stool (Device), urine and saliva (Salivette® Cotton, Synthetic swab, Sarstedt, Germany) samples will be collected in fasting state between 0800 and 0900 h in the morning. Biosampling will also include PBMC isolation as well as extraction of IPS Cells from blood samples. Samples will be stored immediately after collection and preanalytical processing at -80 °C or in liquid nitrogen. The collected feces will be stored immediately after collection at -20 °C.

Evaluation of nutritional and metabolic function

Assessment of the body composition and indirect calorimetry will be conducted by air displacement plethysmography (BodPod; Cosmed GmbH, Germany)[12] and via a ventilatory hood (Quark RMR; Cosmed GmbH, Germany) in fasting state after a 15-minute resting period, respectively. Thereby resting energy expenditure, as well as whole body substrate utilization, can be analyzed [13]. Skin autofluorescence (AF) of the forearm using AGE Reader (DiagnOptics Technologies, Netherlands) will be used to analyze advanced glycemic endproducts (AGEs) as a marker for glycometabolic and oxidative stress [14]. In analogy to the acute period, subcutaneous glucose variability will be measured using the 14-day continuous glucose monitoring system (FreeStyle Libre Pro system; Abbott Diabetes Care, US).

Evaluation of cardio- and cerebrovascular function

Cardiovascular phenotyping also includes a comprehensive morphological and functional cardiac evaluation using 2D-echocardiography (LOGIQ S7 expert. GE Healthcare GmbH). Based on a prespecified SOP, echocardiography will be performed by trained and experienced physicians or certified technicians. Analyses will include left and right cardiac dimensions, volumes and detailed function, valve morphology and function, as well as parameters of the systolic (including strain rate imaging) and diastolic function, description of pericardial effusion and other relevant pathological findings [15–17]. All analyses will be performed by a blinded echo core lab.

Carotid intima-media-thickness (IMT) will be measured as a surrogate marker of arterial wall thickening and subclinical and clinical atherosclerosis in accordance to scientific recommendations[17–19] (Simova I, 2015) using GE's Logic ultrasound device and a 12 MHz linear probe (LOGIQ S7 expert. GE Healthcare GmbH). Dedicated Quality Intima-Media Thickness (QIMT) software will be used for real-time radio frequency detection of the IMT, which automatically measures the intima-media thickness. The software additionally calculates the median ± standard deviation IMT values during several cardiac cycles. This also includes analysis of atherosclerotic plaques (defined as protrusion more than 0.5 mm, IMT more than 50% of the surrounding carotid wall or IMT more than 1.5 mm) at the carotid bifurcation and internal carotid artery.

Vascular retinal changes will be assessed using ultra-wide-angle fundus photography using the Optos California system (Optos GmbH, Düsseldorf, Germany). Ultra-wide-angle fundus photos are highly sensitive in detecting vascular abnormalities even in the outer retinal periphery [20]. At the same time, the method is limits burden to the subject as images can be taken with non-dilated pupil within a few seconds. The fundus photo will be complemented by optic-coherence tomography (OCT) and OCT-angiography (OCT-A). The Zeiss Cirrus OCT with AngioPlex system will be used (Carl Zeiss Meditec, Oberkochen, Germany). OCT enables a three-dimensional re-construction of the neuro-retina and the optic nerve head. OCT-A visualizes the retinal vasculature through flow measurements. Combining OCT and OCT-A results in imaging of the neurovascular unit.

Evaluation of physical activity and neuromuscular function

In accordance to the recommendations of the National Institutes of Health [21] the five domains of neuromuscular function will be assessed by nine-hole peg test (dexterity), hand dynamometer using the Jamar+ digital hand dynamometer (force of the upper limb), Romberg and tandem Romberg test (balance), four-meter gait speed test (locomotion) and two-minute walk test (endurance). In addition, to ensure comparability with the Short Physical Performance Battery in the assessment of lower-extremity endurance and strength, the five-chair-rise test as well as the 2 minute walk-test ares measured. The finger-tapping test assesses upper extremity strength and endurance. Clinically relevant gait parameters and fall-risk will be

assessed using zebris FDM-3 pressure distribution gait platform (Zebris Medical GmbH, Isny, Germany).) Thereby the following spatio-temporal and kinetic parameters are obtained: walking speed, cadence (steps per minute), step length, step time, proportion of standing phase and swing phase, symmetry between both extremities and forces. Moreover physical activity in everyday life will be assessed for seven days using the established ActiGraph* system (ActiGraph, Pensacola, Florida, USA). The device is attached to an elastic waist belt, which is at the level of the pelvis with the position of the accelerometer in the middle axillary line [22]. Subjective fatigue is assessed with PROMS (see above). Frailty is evaluated according to the Clinical Frailty Scale with scores ranging from 1 "Very Fit" and 9 "Terminally III".[23]

Evaluation of pain and neuronal function

All participants will undergo screening with questionnaires for peripheral neuropathy (Michigan Neuropathy Screening Instrument, MNSI)[24] and neuropathic pain (painDETECT-questionnaire, pDQ) [25]. The somatosensory system will be further evaluated by examination of tendon reflexes, tactile sense using monofilaments[26], vibration threshold using a tuning fork as well as warm- and cold detection threshold using QST-certified equipment (TSA-II, Medoc, Israel)[27]. If the results of these measurements are indicative of a somatosensory dysfunction, nerve conduction will be measured using a point-of-care device (DPNcheck, Neurometrix Inc, USA)[28]. For neuroanatomic localization of sensory deficits (eg. central vs. peripheral) a short standardized clinical neurological examination will be performed (Utah Early Neuropathy Scale, UENS) [29]. The neuronal resting state will be measured using a 64-channel dry-electrode EEG-system (actiCap, Brainproducts, Germany and NeurOne Tesla, Mega Electronics, Germany) [30]. EEG caps individually selected according to the participant's head circumference. Usage of conductive gel is usually only applied on ground and reference electrodes. The participant will remain in a relaxed position during the 3 minutes of measuring. To further evaluate the function of small nerve fibers as well as pain pathways a neurophysiological method investigating pain-related laser-evoked potentials (Stimul 1340 solid phase laser, DEKA, Italy)[31,32] will be recorded with the mentioned EEG-system.

Neuropsychological assessment

Cognitive performance of all participants will be examined using a validated neuropsychological test battery. This includes Montreal Cognitive Assessment Test (MOCA) as a screening procedure to determine cognitive deficits (www.mocatest.org) as well as tablet-based test procedure Cantab Connect Test Battery (www.cambridgecognition.com)[33], which allows assessment of simple processing speed, psychomotor speed, figural memory, spatial working memory, executive functions, attention, and verbal memory. Moreover, the Multiple-Choice Vocabulary Intelligence Test[34] as well as subtest 3 of the performance test system will be used to assess the level of the crystallized and fluid intelligence, respectively.[35]

Magnetic resonance

Magnetic resonance imaging (MRI) and MR-spectroscopy (MRS) based on same protocol will be performed in all patients 90 days after inclusion. MRI includes assessment of the brain to detect even small ischemic injuries or functional changes. Cardiac MRI allows the quantification of function and structure including fibrotic remodeling. Changes of fat metabolism were evaluated by abdominal fat imaging and MRS.

Stress test

One of the major research questions of the study is the impact of nutritional or exercise-induced changes of several biomarker on the development of future cardiovascular events. Therefore a nutritional challenge or a physical challenge with a cardio-pulmonary exercise test will be performed in fasting state in randomized order. Therefore, patients without any contraindication will be randomized to either meal challenge or physical challenge. Therefore, stratified randomization will be performed to enable balanced distribution in participation. Strata comprise the five disease entities (ACS, AHF, AKI, AS and T2DM) combined with the three study sides, which results in 15 strata. Randomization lists are generated using a SAS macro specifically programmed for the study and implemented in REDCap system. Patients with current contraindications for either challenge are not randomized but can participate in the other challenge (non-random allocation). All

analyses that include data from the challenge should at least stratify their results according to randomization status.

Participants randomized to the meal challenge will undergo a mixed meal test (20% protein / 25% fat / 55% carbohydrates; 500 kcal) after 12 hours of fasting. Blood samples will be taken 120 minutes after meal intake. In contrast, participants randomized to the physical challenge arm will perform (CPET) using according to guidelines [36-38].with an spiroergometry cycle device (CORTEX Biophysik GmbH, Germany). Any investigator related to the conductance of CPET will be trained according to a pre-specified SOP that harmonized with the SOP established within the German Centre for Cardiovascular Research (DZHK). The exercise protocol was chosen as recommended by current guideline [39]. Also in accordance with current recommendations the exercise test will be finished if one of the following conditions occur: ST depression or elevation (> 0.2 mV), progressive atrial or ventricular arrhythmia or block images, newly occurring atrial fibrillation, drop in heart rate during exercise, lack of increase or drop in RR across 2 exercise levels, drop in oxygen uptake (or oxygen pulse) in spite of increasing the load or due to patients subjective symptoms (severe physical fatigue, chest or thoracic pain, dizziness or severe dyspnea). All analyses will be performed centrally be a blinded CPET core lab. Oxygen saturation will be measured continuously throughout the exercise test via a skin sensor on a finger or on the ear. At regular intervals, a few drops of blood - usually from the ear lobes- will be taken to determine oxygen and carbon dioxide content and metabolic variables (e.g. pH value, bicarbonate and lactate). Venous blood samples will be taken at maximal exercise load, as well as, at 120 minutes after the test.

References

- Hinchcliff M, Beaumont JL, Thavarajah K, Varga J, Chung A, Podlusky S, et al. Validity
 of two new patient-reported outcome measures in systemic sclerosis: Patient-Reported
 Outcomes Measurement Information System 29-item Health Profile and Functional
 Assessment of Chronic Illness Therapy-Dyspnea short form. Arthritis Care Res.
 2011;63: 1620–1628.
- 2. Cella D, Choi SW, Condon DM, Schalet B, Hays RD, Rothrock NE, et al. PROMIS® Adult Health Profiles: Efficient Short-Form Measures of Seven Health Domains. Value Health. 2019;22: 537–544.
- 3. EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16: 199–208.
- 4. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35: 1245–1255.
- 5. Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, McDonell M, et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995;25: 333–341.
- 6. Williams LS, Weinberger M, Harris LE, Clark DO, Biller J. Development of a stroke-specific quality of life scale. Stroke. 1999;30: 1362–1369.
- 7. Distiller LA, Cranston I, Mazze R. First Clinical Experience with Retrospective Flash Glucose Monitoring (FGM) Analysis in South Africa: Characterizing Glycemic Control with Ambulatory Glucose Profile. J Diabetes Sci Technol. 2016;10: 1294–1302.
- 8. Watkins K, Connell CM. Measurement of health-related QOL in diabetes mellitus. Pharmacoeconomics. 2004;22: 1109–1126.
- 9. Bohlscheid-Thomas S, Hoting I, Boeing H, Wahrendorf J. Reproducibility and relative validity of food group intake in a food frequency questionnaire developed for the German part of the EPIC project. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol. 1997;26 Suppl 1: S59–70.
- 10. Keränen A-M, Strengell K, Savolainen MJ, Laitinen JH. Effect of weight loss intervention on the association between eating behaviour measured by TFEQ-18 and dietary intake in adults. Appetite. 2011;56: 156–162.
- 11. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39: 3021–3104.
- 12. Fields DA, Goran MI, McCrory MA. Body-composition assessment via air-displacement plethysmography in adults and children: a review. Am J Clin Nutr. 2002;75: 453–467.
- 13. Haugen HA, Chan L-N, Li F. Indirect calorimetry: a practical guide for clinicians. Nutr Clin Pract. 2007;22: 377–388.
- 14. Mulder DJ, Water TVD, Lutgers HL, Graaff R, Gans RO, Zijlstra F, et al. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced

- glycation endproducts: an overview of current clinical studies, evidence, and limitations. Diabetes Technol Ther. 2006;8: 523–535.
- 15. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16: 233–270.
- 16. Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, Pierard LA, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2013;14: 611–644.
- 17. Gerhard-Herman M, Gardin JM, Jaff M, Mohler E, Roman M, Naqvi TZ, et al. Guidelines for noninvasive vascular laboratory testing: a report from the American Society of Echocardiography and the Society of Vascular Medicine and Biology. J Am Soc Echocardiogr. 2006;19: 955–972.
- 18. Roman MJ, Naqvi TZ, Gardin JM, Gerhard-Herman M, Jaff M, Mohler E, et al. Clinical application of noninvasive vascular ultrasound in cardiovascular risk stratification: a report from the American Society of Echocardiography and the Society of Vascular Medicine and Biology. J Am Soc Echocardiogr. 2006;19: 943–954.
- 19. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27: 2588–2605.
- 20. Talks SJ, Manjunath V, Steel DHW, Peto T, Taylor R. New vessels detected on wide-field imaging compared to two-field and seven-field imaging: implications for diabetic retinopathy screening image analysis. Br J Ophthalmol. 2015;99: 1606–1609.
- 21. Reuben DB, Magasi S, McCreath HE, Bohannon RW, Wang Y-C, Bubela DJ, et al. Motor assessment using the NIH Toolbox. Neurology. 2013;80: S65–75.
- 22. Whitaker KM, Pettee Gabriel K, Jacobs DR Jr, Sidney S, Sternfeld B. Comparison of Two Generations of ActiGraph Accelerometers: The CARDIA Study. Med Sci Sports Exerc. 2018;50: 1333–1340.
- 23. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173: 489–495.
- 24. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17: 1281–1289.
- 25. Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22: 1911–1920.
- 26. Perkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care. 2001;24: 250–256.
- 27. Rolke R, Magerl W, Campbell KA, Schalber C, Caspari S, Birklein F, et al. Quantitative

- sensory testing: a comprehensive protocol for clinical trials. Eur J Pain. 2006;10: 77-88.
- 28. Lee JA, Halpern EM, Lovblom LE, Yeung E, Bril V, Perkins BA. Reliability and validity of a point-of-care sural nerve conduction device for identification of diabetic neuropathy. PLoS One. 2014;9: e86515.
- 29. Singleton JR, Bixby B, Russell JW, Feldman EL, Peltier A, Goldstein J, et al. The Utah Early Neuropathy Scale: a sensitive clinical scale for early sensory predominant neuropathy. J Peripher Nerv Syst. 2008;13: 218–227.
- 30. Mathewson KE, Harrison TJL, Kizuk SAD. High and dry? Comparing active dry EEG electrodes to active and passive wet electrodes. Psychophysiology. 2017;54: 74–82.
- 31. Treede R-D, Lorenz J, Baumgärtner U. Clinical usefulness of laser-evoked potentials. Neurophysiol Clin. 2003;33: 303–314.
- 32. Valeriani M, Pazzaglia C, Cruccu G, Truini A. Clinical usefulness of laser evoked potentials. Neurophysiol Clin. 2012;42: 345–353.
- 33. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53: 695–699.
- 34. Lehrl S. Mehrfachwahl-Wortschatz-Intelligenztest: MWT-A;(Parallelform zum MWT-B). Perimed-Fachbuch-Verlag-Ges.; 1991.
- 35. Sturm W, Willmes K, Horn W. LPS 50+ Leistungsprüfsystem für 50-90-Jährige. Göttingen: Hogrefe. 1993;
- 36. Myers J, Arena R, Franklin B, Pina I, Kraus WE, McInnis K, et al. Recommendations for clinical exercise laboratories: a scientific statement from the american heart association. Circulation. 2009;119: 3144–3161.
- 37. American Thoracic Society, American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167: 211–277.
- 38. American College of Sports Medicine. ACSM's Guidelines for Exercise Testing and Prescription. Lippincott Williams & Wilkins; 2010.
- 39. Beltz NM, Gibson AL, Janot JM, Kravitz L, Mermier CM, Dalleck LC. Graded Exercise Testing Protocols for the Determination of VO2max: Historical Perspectives, Progress, and Future Considerations. J Sports Med. 2016;2016: 3968393.